<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911959</url>
  </required_header>
  <id_info>
    <org_study_id>yan2020-629</org_study_id>
    <nct_id>NCT04911959</nct_id>
  </id_info>
  <brief_title>Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC</brief_title>
  <official_title>Study on the Safety and Effectiveness of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI-positive HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focusing on the current status of clinical treatment of MVI-positive postoperative liver&#xD;
      cancer, single-center clinical trial studies have verified the safety and effectiveness of&#xD;
      TACE combined with lenvatinib in preventing postoperative recurrence of MVI-positive HCC&#xD;
      patients. Explore a new clinical first-line treatment plan for patients with liver cancer&#xD;
      microvascular invasion after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>To evaluate the safety of TACE combined with lenvatinib treatment in preventing postoperative recurrence in patients with MVI-positive HCC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in tumor volume</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>To evaluate the effectiveness of TACE combined with lenvatinib treatment in preventing postoperative recurrence in patients with MVI-positive HCC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival (RFS) evaluation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the recurrence-free survival of patients with MVI-positive HCC after TACE combined with lenvatinib treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease recurrence time evaluation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate the tumor recurrence time of patients with MVI-positive HCC after TACE combined with lenvatinib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival ( OS) evaluation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Overall survival time as assessed by IRC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Lenvatinib</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib is taken orally</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE treatment once</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radical hepatocellular carcinoma was treated 4 weeks (±1 week) ago, and the&#xD;
             pathological diagnosis was HCC after surgery, and MVI was positive&#xD;
&#xD;
          -  Child-Pugh score ≤9 points (Child-Pugh A-B), PS score 0-2 points, BCLC stage A-B&#xD;
&#xD;
          -  The main portal vein is not completely obstructed, or although it is completely&#xD;
             obstructed, the compensatory collateral branches of the portal vein are abundant or&#xD;
             the portal vein blood flow can be restored by implanting the portal vein stent&#xD;
&#xD;
          -  With sufficient organ and bone marrow function, the laboratory test values within 7&#xD;
             days before enrollment meet the requirements&#xD;
&#xD;
          -  Physical fitness score ECOG 0～2&#xD;
&#xD;
          -  Expected survival&gt; 3 months&#xD;
&#xD;
          -  No other systemic malignancies&#xD;
&#xD;
          -  Female subjects of childbearing age or male subjects whose sexual partners are females&#xD;
             of childbearing age must take effective contraceptive measures throughout the&#xD;
             treatment period and 6 months after the treatment period&#xD;
&#xD;
          -  Subjects have informed consent, understand and are willing to cooperate with the trial&#xD;
             protocol, and sign relevant documents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histology includes fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular&#xD;
             carcinoma, cholangiocarcinoma, etc.&#xD;
&#xD;
          -  Severe liver dysfunction (Child-Pugh C), including jaundice, hepatic encephalopathy,&#xD;
             refractory ascites, hepatorenal syndrome, or a history of liver transplantation&#xD;
&#xD;
          -  The main portal vein is completely blocked, and the formation of collateral vessels is&#xD;
             small&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TACE</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>MVI</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Lenvatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

